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these studies, we took a departure from traditional immu-
nohistochemical approaches and instead employed immu-
noassays to quantitatively measure poly(GP) and poly(GA) 
levels in cerebellum, frontal cortex, motor cortex, and/
or hippocampus from 55 C9ORF72 mutation carriers [12 
patients with ALS, 24 with frontotemporal lobar degenera-
tion (FTLD) and 19 with FTLD with motor neuron disease 
(FTLD-MND)]. We additionally investigated associations 
between levels of poly(GP) or poly(GA) and cognitive 
impairment in 15 C9ORF72 ALS patients for whom neu-
ropsychological data were available. Among the neuroana-
tomical regions investigated, poly(GP) levels were highest 
in the cerebellum. In this same region, associations between 
poly(GP) and both neuropathological and clinical features 
were detected. Specifically, cerebellar poly(GP) levels 
Abstract Clinical and neuropathological characteris-
tics associated with G4C2 repeat expansions in chromo-
some 9 open reading frame 72 (C9ORF72), the most com-
mon genetic cause of amyotrophic lateral sclerosis (ALS) 
and frontotemporal dementia, are highly variable. To gain 
insight on the molecular basis for the heterogeneity among 
C9ORF72 mutation carriers, we evaluated associations 
between features of disease and levels of two abundantly 
expressed “c9RAN proteins” produced by repeat-associated 
non-ATG (RAN) translation of the expanded repeat. For 
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were significantly lower in patients with ALS compared to 
patients with FTLD or FTLD-MND. Furthermore, cerebel-
lar poly(GP) associated with cognitive score in our cohort 
of 15 patients. In the cerebellum, poly(GA) levels similarly 
trended lower in the ALS subgroup compared to FTLD or 
FTLD-MND subgroups, but no association between cere-
bellar poly(GA) and cognitive score was detected. Both cer-
ebellar poly(GP) and poly(GA) associated with C9ORF72 
variant 3 mRNA expression, but not variant 1 expression, 
repeat size, disease onset, or survival after onset. Overall, 
these data indicate that cerebellar abnormalities, as evi-
denced by poly(GP) accumulation, associate with neuro-
pathological and clinical phenotypes, in particular cognitive 
impairment, of C9ORF72 mutation carriers.
Keywords Amyotrophic lateral sclerosis · C9ORF72 
repeat expansion · c9RAN proteins · Cognition · Dipeptide 
repeat proteins · Frontotemporal dementia · Frontotemporal 
lobar degeneration · Neuropathological diagnosis · Repeat-
associated non-ATG translation
Introduction
Amyotrophic lateral sclerosis (ALS), the most common 
motor neuron disease (MND), is characterized by progres-
sive upper and lower motor neuron weakness, typically 
resulting in death from ventilatory failure within three to 
five years of onset. In addition, up to 50 % of ALS patients 
develop cognitive impairments consistent with frontotem-
poral dementia (FTD) [15]. FTD, the clinical presentation 
of frontotemporal lobar degeneration (FTLD), encom-
passes a group of disorders characterized by changes in 
personality, behavior, and/or language. A proportion of 
FTD patients also develop ALS [33]. The clinical overlap 
between ALS and FTD, combined with neuropathological 
similarities—TDP-43 pathology is present in the majority 
of ALS cases and the most common pathological subtype 
of FTLD (FTLD-TDP)—suggest ALS and FTD are part of 
a disease spectrum. This concept was strengthened by the 
discovery that a G4C2 repeat expansion in chromosome 9 
open reading frame 72 (C9ORF72) is the most common 
genetic cause of ALS and FTD [10, 28]. The molecular 
basis for the clinical variation among C9ORF72 patients is 
not known. In addition to TDP-43 pathology, patients with 
“c9FTD/ALS” develop cerebellar and hippocampal TDP-
43-negative neuronal inclusions that are positive for p62, 
ubiquitin, and select ubiquitin-binding proteins [1, 5, 6, 23, 
25]. Other hallmark features of c9FTD/ALS result from 
the accumulation of sense G4C2 or antisense G2C4 repeat-
containing RNA. These transcripts form nuclear RNA foci 
in cells throughout the central nervous system and are sub-
ject to repeat-associated non-ATG (RAN) translation [3, 
10, 11, 21, 22, 43]. RAN translation of sense and antisense 
repeats, which occurs in all reading frames in the absence 
of an initiating ATG codon, yields five proteins of repeat-
ing dipeptides (GP, GA, GR, PR, PA), collectively referred 
to as c9RAN proteins. c9RAN proteins are a major com-
ponent of TDP-43-negative, p62-positive inclusions [18]. 
Indeed, c9RAN protein pathology, in particular inclusions 
of poly(GP) or poly(GA), is abundant in cerebellum, hip-
pocampus, and neocortical regions [3, 16, 18, 21, 22, 30, 
43].
Several c9RAN proteins are toxic in a variety of models, 
thus implicating RAN translation as a mechanism of dis-
ease [12, 14, 19, 20, 35, 37, 40–43]. However, there have 
been conflicting reports on clinical and neuropathological 
correlations with c9RAN protein pathology in C9ORF72 
mutation carriers [9, 16, 18, 30]. For instance, among three 
studies, no associations between poly(GA) inclusion bur-
den in various brain regions and either neurodegeneration, 
clinical phenotype, or neuropathological phenotype were 
detected [9, 16, 18]. Conversely, it was recently reported 
that, in a cohort of 14 C9ORF72 patients, poly(GA) inclu-
sions in cerebellar granule cells were significantly more 
abundant in patients with FTLD compared to patients with 
MND or FTLD-MND [30]. These findings highlight the 
need for more thorough evaluations of the various c9RAN 
proteins in c9FTD/ALS, and that neuroanatomical regions 
not typically studied, such as the cerebellum, should be 
included in these investigations. Indeed, while often over-
looked, neuroimaging and clinical evidence support the 
involvement of the cerebellum in cognitive and affective 
regulation [13]. Combined with cerebellar atrophy emerg-
ing as a distinguishing feature of c9FTD/ALS compared to 
sporadic or other familial forms of these diseases [17, 32, 
38], and our discovery of robust cerebellar transcriptome 
changes in c9ALS [27], the question arises as to whether 
cerebellar pathology contributes to cognitive dysfunction 
in C9ORF72 mutation carriers. We thus evaluated whether 
poly(GP) and poly(GA), which are abundantly expressed 
in the cerebellum, associate with neuropathological and 
clinical characteristics of patients with a C9ORF72 repeat 
expansion.
Materials and methods
Study design and participants
To evaluate associations between c9RAN protein levels and 
neuropathological diagnosis, we included all cases in the 
Mayo Clinic Jacksonville brain bank who were identified 
as C9ORF72 expansion carriers by repeat-primed PCR [10] 
and by immunostaining for poly(GP) pathology [3], and 
for whom frozen tissue from the cerebellum, frontal cortex, 
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motor cortex, and hippocampus was available (n = 55; 
Table 1). Family history of disease was considered posi-
tive if patients were known to have a first or second degree 
relative with ALS, FTLD or mixed features of both. Age at 
onset was estimated based on the appearance of first dis-
ease symptoms.
Of the 55 patients in our overall cohort, 15 composed 
our clinical cohort. An ALS-focused selection established 
a C9ORF72 patient cohort in which cognitive status ranged 
from normal to definitely abnormal. Study patients in the 
clinical cohort were ascertained from 2009 to 2014 on 
the basis of a diagnosis of ALS meeting El Escorial crite-
ria, participation in the Mayo Clinic ALS Center deeded 
autopsy program, and genetically and pathologically con-
firmed to have a C9ORF72 repeat expansion (n = 15; 
Table 4; Supplementary Table 1). All patients in the clinical 
cohort were followed for multiple visits by the same neu-
rologist (KBB) from initial encounter through advanced 
disease stage with severe, global disability. Assessments of 
cognitive function were derived from independent review 
of clinical records and test results by four evaluators, a neu-
rologist (KBB) and three neuropsychologists (JAL, OP, and 
BKR), who all had access to the same clinical data. Clini-
cal records for all patients included observations by clinical 
staff and family members involved in the patients’ care with 
regard to cognition and behavior, and for nine of the 15 
patients, data from the ALS Cognitive Behavioral Screen, 
a validated neuropsychological screening instrument [39], 
and/or a full neuropsychological examination (Supplemen-
tary Table 1). Examiners were aware of the patient’s diag-
nosis of c9ALS but were blinded to data on c9RAN protein 
levels. Owing to varied data available across the cohort on 
patients’ neuropsychological status, each patient with ALS 
was independently assessed by each of the evaluators on a 
0–2 scale (0 = normal, 1 = mild or questionable impair-
ment, or 2 = definitely abnormal) with respect to cognition. 
Scores were based on assessment of executive function, 
verbal fluency, and memory as supported by observational 
and quantitative data. Given our comparisons of cognitive 
status with autopsy findings, the assigned scores reflected 
the evaluator’s assessments of the patient’s cognitive func-
tion in late stage disease (i.e. near death with severe, global 
disability) based on available supporting data, which in all 
cases included caregiver information regarding the patient’s 
cognitive status at an advanced stage of disease. The rat-
ing of the 15 patients by the four evaluators resulted in 90 
potential pairwise agreements; pairwise agreement for the 
cognitive score was 80 % (72/90). The final cognitive score 
for each patient represents the average of the scores of the 
four evaluators.
Written informed consent was obtained from all partici-
pants or their legal next of kin if they were unable to give 
written consent, and biological samples were obtained with 
ethics committee approval.
Immunoassay analysis of c9RAN proteins in tissue 
homogenates
Brain homogenates were prepared as previously described 
[2]. In brief, approximately 50 mg of cerebellum, frontal 
cortex, motor cortex, or hippocampus tissue was homog-
enized in cold RIPA buffer (25 mM Tris–HCl pH 7.6, 
150 mM NaCl, 1 % sodium deoxycholate, 1 % Nonidet 
P-40, 0.1 % sodium dodecyl sulfate, protease and phos-
phatase inhibitors) and sonicated on ice. Homogenates 
were cleared by centrifugation at 100,000g for 30 min at 
4 °C. The supernatant was collected and the concentration 
of RIPA-soluble proteins was determined by BCA assay. 
The resulting pellet was resuspended in RIPA buffer and, 
to prevent carry-over, re-sonicated and re-centrifuged. The 
RIPA-insoluble pellet was then extracted using 7 M urea 
buffer, sonicated and centrifuged at 100,000g for 30 min at 
22 °C. The protein concentration of the urea-soluble super-
natant was determined by Bradford assay.
Poly(GP) levels in lysates were measured using a pre-
viously described sandwich immunoassay that utilizes 
Table 1  Characteristics of C9ORF72 repeat expansion carriers
Data presented as median (IQR) or number (%)
For some patients, information was unavailable for age of onset and survival after onset (n = 3, 2 with FTLD and 1 with FTLD-MND) and fam-
ily history (n = 8, 1 with ALS, 4 with FTLD and 3 with FTLD-MND)
ALS amyotrophic lateral sclerosis, FTLD frontotemporal lobar degeneration, FTLD-MND frontotemporal lobar degeneration with motor neuron 
disease
Overall cohort (n = 55) ALS (n = 12) FTLD (n = 24) FTLD-MND (n = 19)
Women 30 (55 %) 9 (75 %) 8 (33 %) 8 (42 %)
Age of onset (years) 61.6 (52.8–67.1) 51.0 (47.8–65.5) 66.2 (56.3–70.0) 57.5 (54.2–65.0)
Age of death (years) 66.5 (59.1–72.6) 56.0 (49.9–67.1) 72.4 (66.2–80.6) 62.0 (59.9–68.1)
Survival after onset (years) 5.0 (2.7–8.0) 2.4 (1.5–3.2) 7.3 (5.7–9.8) 4.2 (2.6–6.7)
Family history 22 (47 %) 4 (36 %) 9 (45 %) 9 (56 %)
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an affinity purified rabbit polyclonal poly(GP) antibody 
(Rb9259) and Meso Scale Discovery (MSD) electrochemi-
luminescence detection technology [34]. This assay specifi-
cally detects poly(GP) and no other c9RAN protein [34]. 
Homogenates were diluted in Tris-buffered saline (TBS) 
and equal amounts of protein for all samples from the same 
neuroanatomical region and fraction were tested in dupli-
cate wells. Serial dilutions of recombinant (GP)8 in TBS 
were used to prepare the standard curve. Response values 
corresponding to the intensity of emitted light upon elec-
trochemical stimulation of the assay plate using the MSD 
QUICKPLEX SQ120 were acquired and background 
corrected using the average response from homogen-
ates obtained from non-C9ORF72 repeat expansion carri-
ers prior to interpolation of poly(GP) levels [presented as 
ng of poly(GP) per mg protein] using the standard curve. 
Poly(GA) levels in homogenates were similarly measured 
with an MSD-based sandwich immunoassay that utilizes 
a purified rabbit polyclonal poly(GA) antibody (Rb4333) 
provided by the Cleveland lab and a mouse monoclo-
nal poly(GA) antibody (clone 5F2, [16]) provided by the 
Edbauer lab. Serial dilutions of recombinant (GA)50 were 
used for the standard curve. This assay specifically detects 
poly(GA) and no other c9RAN protein (Supplementary 
Fig. 1).
Immunohistochemistry and analysis of poly(GP) 
and phosphorylated TDP‑43 pathology
To compare poly(GP) levels evaluated by immunoassay to 
poly(GP) pathology measured by immunohistochemistry, 
cerebellar tissue from 35 C9ORF72 repeat expansion car-
riers were immunostained for poly(GP). In addition, phos-
phorylated TDP-43 (pTDP-43) pathology was evaluated in 
frontal cortex and hippocampus tissues from the 15 patients 
in our clinical cohort to study associations of pTDP-43 
with cognitive score or neuropathological diagnosis. Five 
micron thick slices were cut from formalin-fixed, paraffin-
embedded tissue, and mounted on glass slides. After dry-
ing, slides were deparaffinized and rehydrated in xylene 
and alcohol washes before being steamed for 30 min 
in deionized water for antigen retrieval. All slides were 
processed on a Dako Autostainer with the Dako EnVi-
sion™+ system and 3′3-diaminobenzidine chromogen. 
Slides were stained with rabbit polyclonal poly(GP) anti-
serum (Rb5823, 1:5000) [3], rabbit polyclonal poly(GA) 
antiserum (Rb9880, 1:30,000) [42], or a mouse mono-
clonal antibody against TDP-43 phosphorylated at S409/
S410 (1:5000, Cosmo Bio Co., Tokyo, Japan), then coun-
terstained with Lerner hematoxylin and coverslipped with 
Cytoseal permanent mounting media.
To quantify poly(GP) pathology in the cerebellum, high 
resolution images of immunostained slides were captured 
using an Aperio ScanScope XT scanner and analyzed using 
ImageScope software (Leica Biosystems, Buffalo Grove, 
IL). For each case, twenty 1 mm2 annotated boxes were 
placed throughout the internal granule cell layer, analyzed 
using a color deconvolution algorithm tuned to strong 
immunopositivity per the 3′3-diaminobenzidine chromo-
gen, and averaged among the 20 boxes. pTDP-43 pathol-
ogy in the frontal cortex and hippocampus was similarly 
quantified from high resolution images using ImageScope 
software. In the hippocampus and frontal cortex, traced 
regions of interest included the dentate fascia, the dentate 
fascia with the hippocampus proper (CA4-subiculum), and 
the cross-sectional midfrontal gyrus (spanning crest to sul-
cal depth). All images were subsequently processed with a 
color deconvolution algorithm specifically tuned to pTDP-
43 immunoreactivity.
Measurement of C9ORF72 transcript variant 1 or 
transcript variant 3 mRNA
Total RNA was extracted from frozen cerebellum and 
frontal cortex using the RNeasy Plus mini kit (Qiagen), 
following manufacturer’s protocols. RNA quality and 
quantity were determined with an Agilent 2100 Bioana-
lyzer using the RNA Nano Chip (Agilent Technologies). 
High quality RNA was obtained from the cerebellum 
and frontal cortex of 49 and 48 patients, respectively. 
We performed a reverse transcription reaction with 
300 ng of RNA as template, using an equal ratio of Ran-
dom Hexamers and Oligo dT primers and the Super-
Script III Kit (Invitrogen). Quantitative real-time PCR 
was then done on an ABI7900 PCR system (Applied 
Biosystems) using TaqMan gene expression assays (Life 
Technologies) in accordance with the manufacturer’s 
recommendations. We assessed neuronal markers syn-
aptophysin (SYP; Hs00300531_m1) and microtubule-
associated protein 2 (MAP2; Hs00258900_m1) as well 
as C9ORF72 transcript variant 3 (NM_001256054.2; 
Hs00948764_m1). Using R Statistical Software (ver-
sion 3.2.0; R Foundation for Statistical Computing), 
we calculated the median of replicates and took the 
geometric mean of neuronal markers, and subsequently 
determined expression levels relative to control sub-
jects utilizing the ΔΔ Ct method. For transcript vari-
ant 1 (NM_145005.6), digital molecular barcoding 
(NanoString Technologies) was performed by the 
manufacturer using 100 ng of RNA as template. The 
NanoStringNorm R package and nSolver Analysis Soft-
ware (NanoString Technologies, version 2.5) were used 
to account for technical assay variation using the geo-
metric mean method. Maximum background subtraction 
was then performed, and data was normalized to the 
geometric mean of neuronal markers SYP and MAP2.
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Measurement of C9ORF72 repeat size
For 53 patients for whom high quality DNA from the cer-
ebellum and frontal cortex was available, the size of the 
G4C2 repeat expansion in these tissues was determined by 
Southern blotting as described elsewhere [36].
Statistical analysis
In a cohort of 35 patients with the C9ORF72 repeat expan-
sion, associations of cerebellar poly(GP) levels quantified 
by immunoassay with poly(GP) immunopositivity quanti-
fied from immunostained cerebellar sections were evalu-
ated using a Spearman’s test of correlation; Spearman’s 
correlation coefficient r and 95 % confidence intervals (CI) 
were estimated.
In our cohort of 55 patients, levels of poly(GP) were 
compared among neuroanatomical regions (i.e. cerebel-
lum, frontal cortex, motor cortex, and hippocampus) using 
a Friedman rank sum test. This was followed by a paired 
Wilcoxon signed rank test for pairwise comparisons when 
significant differences were encountered (p < 0.0083 con-
sidered significant after Bonferroni correction). Associa-
tions between soluble and insoluble poly(GP) or poly(GA) 
levels in a given neuroanatomical region were evaluated 
using a Spearman’s test of correlation. The difference 
between soluble and insoluble poly(GP) as a percentage 
of total poly(GP) levels was evaluated using a Wilcoxon 
signed rank test, and the same was done for poly(GA).
For a given neuroanatomical area, we assessed associa-
tions of poly(GP) or poly(GA) with six variables [i.e. dis-
ease subgroups (i.e. ALS, FTLD, FTLD-MND), C9ORF72 
expansion size, C9ORF72 variant 1, C9ORF72 variant 3, age 
of onset, and survival after onset]. To adjust for multiple test-
ing and control the family-wise error rate at 5 %, a Bonfer-
roni correction was utilized separately for each outcome, and 
thus p < 0.0083 was considered significant. A Kruskal–Wallis 
rank sum test was performed to determine whether poly(GP) 
or poly(GA) levels differed significantly among disease sub-
groups, and when this test was significant, a Wilcoxon rank 
sum test was used for pairwise comparisons (p < 0.017 con-
sidered significant after Bonferroni correction). To assess 
associations between poly(GP) or poly(GA) levels and repeat 
size, C9ORF72 transcript variant 1 or 3 expression, and age 
of onset of the C9ORF72 expansion, a Spearman’s test of 
correlation was used. Associations between poly(GP) or 
poly(GA) levels and survival after disease onset were inves-
tigated using Cox proportional hazards regression models. 
Hazard ratios and 95 % CIs were estimated. Since all patients 
were deceased no censoring was necessary. Models were 
adjusted for age of onset and disease subgroup. Poly(GP) or 
poly(GA) levels were considered as dichotomous categorical 
variables using the median as the cut-off point.
In our cohort of 15 patients for whom cognitive status 
was evaluated, we assessed associations of seven outcomes 
[i.e. total poly(GP), soluble poly(GP), insoluble poly(GP), 
total poly(GA), soluble poly(GA), insoluble poly(GA), 
and pTDP-43 pathology] with two variables (i.e. cognitive 
score and neuropathological diagnosis). Associations of 
poly(GP), poly(GA) or pTDP-43 with cognitive score were 
assessed using Spearman’s test of correlation, and associa-
tions with neuropathological diagnosis were assessed using 
a Wilcoxon rank sum test (p < 0.025 considered significant 
after Bonferroni correction).
In a secondary analysis, associations between poly(GP) 
levels in all evaluated neuroanatomical regions and pTDP-
43 pathology in the frontal cortex or hippocampus were 
analyzed using Spearman’s test of correlation (p < 0.025 
considered significant after Bonferroni correction). Asso-
ciations between cerebellar poly(GA) levels and pTDP-
43 pathology in the frontal cortex or hippocampus were 
similarly assessed. A Wilcoxon rank sum test was used 
for pairwise comparisons between ALS and FTLD-MND 
subgroups in the clinical cohort with respect to sex, age 
of onset, survival after onset, education, and cognitive 
score (p < 0.01 considered significant after Bonferroni 
correction).
Results
Soluble and insoluble poly(GP) are detected in various 
neuroanatomical regions and are highest in the 
cerebellum
We previously reported, and show in Fig. 1a–d, that 
poly(GP) inclusions are detected in abundance in the cer-
ebellum, neocortex, and hippocampus of C9ORF72 muta-
tion carriers by immunohistochemistry [3]. In the present 
study, we utilized an immunoassay to measure levels of 
poly(GP) in various neuroanatomical regions. A compari-
son of cerebellar poly(GP) levels determined using this 
biochemical approach with poly(GP) immunopositivity 
in stained cerebellar sections from 35 C9ORF72 muta-
tion carriers revealed a significant correlation between 
these two measures (Supplementary Table 2). One of the 
advantages of biochemical analyses of poly(GP) burden 
is the ability to measure different forms of the protein in a 
quantitative manner. Since soluble protein oligomers, like 
insoluble forms of aggregating proteins, may be patho-
genic, we measured both soluble and insoluble poly(GP) 
levels in cerebellum, frontal cortex, motor cortex, and hip-
pocampus homogenates sequentially extracted with RIPA 
buffer (soluble fraction) and urea buffer (insoluble frac-
tion). As shown in Fig. 1e–g, levels of soluble and insolu-
ble poly(GP) were significantly higher in the cerebellum 
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compared to the other neuroanatomical regions. Given that 
a significant correlation existed between these forms of 
poly(GP) in all regions (Supplementary Table 3), the analy-
ses presented below are limited to total poly(GP) levels for 
simplicity. Data on soluble and insoluble poly(GP) can be 
found in the Electronic Supplementary Material (Supple-
mentary Tables 4–8).
Cerebellar poly(GP) levels are significantly lower 
in C9ORF72 mutation carriers with ALS compared 
to patients with FTLD or FTLD‑MND
We next evaluated whether poly(GP) levels in the cerebel-
lum, frontal cortex, motor cortex, or hippocampus differ 
among patients neuropathologically diagnosed with ALS 
(n = 12), FTLD (n = 24), or FTLD-MND (n = 19). Of 
interest, poly(GP) levels in the cerebellum were signifi-
cantly lower in the ALS subgroup (median 1481 ng/mg, 
IQR 1083–1758) compared to the FTLD (median 3501 ng/
mg, IQR 1864–4652, p = 0.001) or FTLD-MND (median 
4014 ng/mg, IQR 2119–5002, p = 0.001) subgroups 
(Table 2; Fig. 2). In the frontal cortex, poly(GP) levels also 
differed based on neuropathological subtype, although the 
expression profile varied from that observed in the cerebel-
lum; patients with FTLD-MND (median 859 ng/mg, IQR 
575–971) had significantly higher poly(GP) levels in the 
frontal cortex compared to patients with FTLD (median 
452 ng/mg, IQR 358–546, p = 0.001) (Table 2; Fig. 2). No 
differences in poly(GP) levels among disease subgroups 
were detected in the motor cortex or hippocampus (Table 2; 
Fig. 2).
Cerebellar poly(GP) associates with C9ORF72 
transcript variant 3 expression but not with expression 
of variant 1 or with repeat size
Because our studies uncovered associations between cer-
ebellar or frontal cortical poly(GP) and the neuropathologi-
cal diagnosis of C9ORF72 patients, we sought to identify 
factors that influence poly(GP) levels. We first investi-
gated associations between poly(GP) and repeat size of the 
C9ORF72 expansion and found no association between 
these two variables in either the cerebellum or the frontal 
cortex (Table 3). We next evaluated associations between 
poly(GP) and transcript levels for C9ORF72 variant 1 or 
variant 3. The G4C2 repeat is located between exons 1a and 
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Fig. 1  Comparison of poly(GP) levels in different neuroanatomical 
regions of C9ORF72 mutation carriers. a–d Poly(GP)-immunoreac-
tive inclusions in the cerebellum (a), frontal cortex (b), motor cortex 
(c) and hippocampus (d) of a C9ORF72 repeat expansion carrier. 
Scale bar 5 µm. e–g Levels of total poly(GP) (e), soluble poly(GP) 
(f), or insoluble poly(GP) (g) in cerebellum, frontal cortex, motor cor-
tex, and hippocampus of patients with C9ORF72 repeat expansions 
(n = 55). The median in a given group is denoted by a solid horizon-
tal line
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1b; if exon 1a is used, as is the case for variants 1 and 3, 
the repeat is located in intron 1 and is transcribed. If exon 
1b is used, the repeat is located in the promoter region and 
is not transcribed (variant 2; NM_018325.4). In the cere-
bellum, poly(GP) levels associated with variant 3 (r 0.38, 
95 % CI 0.10–0.62, p = 0.007; Fig. 3) but not with variant 
1 (Table 3). In the frontal cortex, no association between 
poly(GP) levels and C9ORF72 transcript variant 1 or vari-
ant 3 was detected (Table 3). 
Cerebellar poly(GP) associates with cognitive 
impairment
Despite the associations between poly(GP) in the cer-
ebellum or frontal cortex and neuropathological subgroup, 
poly(GP) levels in these neuroanatomical regions did not 
associate with age of disease onset in our overall cohort 
of patients (Table 3). Furthermore, survival after onset, 
adjusted for age of onset and disease subgroup, was not 
associated with poly(GP) in these regions (Supplementary 
Table 6).
Since poly(GP) levels could nevertheless influence the 
clinical phenotype of patients, we examined associations 
between poly(GP) levels in different neuroanatomical 
regions and cognitive impairment. These studies were car-
ried out on 15 c9ALS patients for whom neuropsychologi-
cal data was available (Table 4; Supplementary Table 1). 
Ten of the 15 patients in this clinical cohort presented with 
ALS (67 %), four with ALS accompanied by cognitive 
impairment (27 %), and one with behavioral variant FTD 
(bvFTD-ALS, 7 %; Supplementary Table 1). At autopsy, 
nine patients were neuropathologically diagnosed with 
ALS (60 %) and six with FTLD-MND (40 %). No signifi-
cant differences in sex, age of disease onset, survival after 
onset, education, or cognitive score were observed between 
the ALS and FTLD-MND subgroups (Table 4).
Notably, an association between poly(GP) levels in the 
cerebellum and cognitive score was detected (r = 0.67, 
95 % CI 0.22–0.88, p = 0.009) (Table 5; Fig. 4a). In con-
trast, poly(GP) levels in frontal cortex, motor cortex, 
and hippocampus did not associate with cognitive score 
(Table 5). As anticipated, an association between pTDP-
43 pathology in the frontal cortex and cognitive score 
was observed (r = 0.58, 95 % CI 0.09–0.85, p = 0.025) 
(Table 5).
Similarly to what was observed in the 55 C9ORF72 
mutation carriers, cerebellar poly(GP) levels in patients 
with ALS (median 1122 ng/mg, IQR 1005–1708) were 
significantly lower compared to patients with FTLD-MND 
(median 3583 ng/mg, IQR 2901–4139, p = 0.0008) in the 
smaller clinical cohort (Table 5; Fig. 4b). In the other neu-
roanatomical regions, no difference in poly(GP) levels was 
detected between neuropathological subgroups (Table 5). Ta
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As would be expected, pTDP-43 pathology in frontal cor-
tex and hippocampus was significantly more abundant in 
the FTLD-MND subgroup compared to the ALS subgroup 
(Table 5).
We additionally investigated potential relationships 
between c9RAN protein expression and pTDP-43 pathol-
ogy. No association between poly(GP) levels in the fron-
tal cortex or hippocampus and pTDP-43 pathology in these 
same regions was detected. Likewise, poly(GP) levels in 
the motor cortex did not associate with frontal cortical or 
hippocampal pTDP-43 pathology. However, in line with 
our findings that poly(GP) levels in the cerebellum asso-
ciated with neuropathological diagnosis, as did pTDP-
43 pathology in the frontal cortex and hippocampus, we 
detected an association of cerebellar poly(GP) levels with 
pTDP-43 pathology in the frontal cortex (r = 0.69, 95 % 
CI 0.22–0.92, p = 0.005) or hippocampus (r = 0.69 95 % 
CI 0.25–0.89, p = 0.005) (Supplementary Table 8).
Associations of cerebellar poly(GA) 
with neuropathological and clinical features
Given our findings above and the fact that poly(GA) 
pathology is abundant in the cerebellum (Fig. 5a), and 
given a recent report showing that poly(GA) inclusion bur-
den in cerebellar granule cells correlated with neuropatho-
logical subgroup [30], we investigated whether cerebellar 
poly(GA) levels assessed by immunoassay differ based on 
neuropathological diagnosis or cognitive score in our case 
series. As observed for cerebellar poly(GP), there existed 
a significant correlation between soluble and insoluble 
poly(GA) levels in the cohort of 55 C9ORF72 mutation 
carriers (Supplementary Table 9). However, the solubility 
profile of poly(GA) differed from that of poly(GP); while 
soluble poly(GP) levels were significantly higher than 
insoluble poly(GP) levels in the cerebellum, the opposite 
was observed for poly(GA) (Fig. 6).
Fig. 2  Poly(GP) levels are 
significantly lower in the cer-
ebellum of C9ORF72 mutation 
carriers with ALS compared to 
patients with FTLD or FTLD-
MND. Shown are total levels 
of poly(GP) in the indicated 
neuroanatomical regions by 
disease subgroup [amyo-
trophic lateral sclerosis (ALS), 
n = 12; frontotemporal lobar 
degeneration (FTLD), n = 24; 
and FTLD with motor neuron 
disease (FTLD-MND); n = 19]. 
Poly(GP) levels in the cerebel-
lum were significantly lower in 
patients with ALS compared to 
patients with FTLD or FTLD-
MND. In the frontal cortex, 
poly(GP) levels were signifi-
cantly higher in the FTLD-
MND subgroup compared to the 
FTLD subgroup. The median in 
a given group is denoted by a 
solid horizontal line
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Upon comparing cerebellar poly(GA) among neuro-
pathological subgroups, differences in poly(GA) levels 
among subgroups neared statistical significance but the p 
value (p = 0.0088) did not meet the cut-off (p < 0.0083) 
established by Bonferroni correction. Nevertheless, 
total poly(GA) levels trended lower in the ALS sub-
group (median 8877 ng/mg, 8327–10,616) in compari-
son to the FTLD (median 11,723 ng/mg, 10,666–15,054) 
or FTLD-MND (median 11,677 ng/mg, 10,627–13,673) 
subgroups (Fig. 5b; Supplementary Table 10). Compared 
to cerebellar poly(GP), the difference in poly(GA) levels 
among subgroups was less robust. Whereas poly(GP) lev-
els in FTLD and FTLD-MND were approximately 2.5-fold 
higher than in ALS (Fig. 2), a 1.3-fold increase in poly(GA) 
levels was detected in FTLD and FTLD-MND compared to 
ALS (Fig. 5b).
Consistent with total poly(GP) in the cerebellum, total 
poly(GA) levels associated with C9ORF72 variant 3 (r 
0.46, 95 % CI 0.22–0.66, p = 0.0009; Fig. 5c) but not with 
C9ORF72 variant 1, repeat size, age of onset, or survival 
after onset (Supplementary Tables 11 and 12). In contrast 
to cerebellar poly(GP), total poly(GA) levels did not asso-
ciate with cognitive score or with neuropathological diag-
nosis (ALS vs. FTLD-MND) in our clinical cohort of 15 
patients (Supplementary Table 13). An association between 
soluble poly(GA) and neuropathological diagnosis was 
nonetheless detected in this smaller cohort (Supplementary 
Table 13). Furthermore, poly(GA) levels in the cerebellum 
associated with pTDP-43 pathology in the frontal cortex or 
hippocampus (Supplementary Table 14), as did cerebellar 
poly(GP).
Discussion
Neuropathologic and clinical diversity characterize 
C9ORF72 repeat expansion carriers, but the molecu-
lar basis for this variation remains elusive. Our studies 
reveal intriguing findings involving c9RAN proteins in 
the cerebellum. We show that cerebellar poly(GP) lev-
els were significantly lower in ALS patients compared 
to FTLD and FTLD-MND patients. This is not likely 
due to the shorter disease duration of ALS, which could 
afford less time for c9RAN proteins to accumulate, since 
poly(GP) levels in the frontal cortex, motor cortex, and 
hippocampus did not similarly differ between ALS and 
FTLD or FTLD-MND subgroups. Rather, the results sug-
gest that expression of the C9ORF72 repeat expansion 
in cerebellum influences neuropathological phenotypes 
and this may consequently influence clinical features. 
Indeed, we found that cerebellar poly(GP) levels asso-
ciated with cognitive impairment. Whether this occurs 
as a direct result of poly(GP) accumulation, or whether 
poly(GP) serves as a marker for aberrant events trig-
gered by C9ORF72 repeat expansions, is not yet known. 
Similarly to our observations with poly(GP), cerebellar 
poly(GA) levels trended lower in patients with ALS com-
pared to patients with FTLD or FTLD-MND, but the p 
value narrowly exceeded the threshold of significance 
after adjustment for multiple comparisons (p < 0.0083). 
Table 3  Associations of total poly(GP) levels with C9ORF72 expan-
sion size, C9ORF72 variants 1 and 3, and age at onset
Spearman’s r correlation coefficients, 95 % confidence intervals 
(CIs), and p values are presented. In total, associations with six vari-
ables were examined (i.e. disease subgroups, C9ORF72 expansion 
size, C9ORF72 variant 1, C9ORF72 variant 3, age of onset, and sur-
vival after onset), and therefore p values lower than 0.0083 were con-
sidered significant after Bonferroni correction
Of note, only four of those variables are shown in this table
p values denoted by bold remain significant after adjustment for mul-
tiple testing
Spearman’s r (95 % CI) p value
Cerebellum
 C9ORF72 expansion size −0.19 (−0.47 to 0.11) 0.17
 C9ORF72 variant 1 0.21 (−0.08 to 0.48) 0.14
 C9ORF72 variant 3 0.38 (0.10 to 0.62) 0.007
 Age at onset 0.02 (−0.28 to 0.30) 0.91
Frontal cortex
 C9ORF72 expansion size −0.09 (−0.35 to 0.18) 0.50
 C9ORF72 variant 1 0.13 (−0.17 to 0.41) 0.37
 C9ORF72 variant 3 0.27 (−0.03 to 0.52) 0.07
 Age at onset −0.28 (−0.56 to 0.005) 0.04
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Fig. 3  Cerebellar poly(GP) associates with C9ORF72 transcript vari-
ant 3 expression. Associations of total poly(GP) levels in the cerebel-
lum with expression of C9ORF72 transcript variant 3 (n = 49). The 
straight line is a linear regression line
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This is likely due to the fact that differences in poly(GA) 
levels among disease subgroups were less robust than 
those observed for poly(GP), an observation that may 
also explain the lack of association between poly(GA) 
and cognitive impairment in our clinical cohort. A larger 
number of patients may be required to detect potential 
associations between poly(GA) levels and neuropatho-
logical diagnosis or cognitive score. Indeed, while find-
ings in our retrospectively identified clinical cohort are of 
particular interest, further validation in larger cohorts of 
c9ALS and c9FTD patients in whom detailed cognitive 
and behavioral data are available is warranted in order 
to define contributions of c9RAN proteins to clinical 
phenotypes.
Our study supports the need for more sensitive and 
quantitative approaches when evaluating the relationship 
between putatively pathologic proteins and disease pheno-
types. Previous studies that utilized semi-quantitative grad-
ing systems of c9RAN protein pathology, in particular for 
poly(GA), did not detect associations with clinical or neu-
ropathological features [9, 16, 18]. It must be recognized, 
however, that semi-quantitative analyses may not be suffi-
ciently sensitive to discern differences among patient sub-
groups, especially when cohorts are small. More recently, 
Table 4  Characteristics of patients in the clinical cohort
Data presented as median (IQR) or number (%)
Percentages may not sum to 100 % because of rounding
p values lower than 0.01 were considered significant after Bonferroni correction
ALS amyotrophic lateral sclerosis, FTLD-MND frontotemporal lobar degeneration with motor neuron disease
* Education was assumed to be 19 years for three patients with a degree of MD, DDS, or JD
Overall cohort (n = 15) ALS (n = 9) FTLD-MND (n = 6) p value
ALS vs. FTLD-MND
Women 8 (53 %) 6 (66 %) 2 (33 %) 0.31
Age of onset (years) 58 (51–66) 52 (49–67) 61 (58–65) 0.55
Survival after onset (years) 2.3 (1.7–3.7) 1.8 (1.5–3.7) 2.5 (2.2–3.4) 0.60
Education (years) 15 (14–17*) 14 (13–16) 16 (14–19) 0.35
Cognitive score 1.25 (0.25–2.00) 0.50 (0.00–1.50) 2.00 (1.44–2.00) 0.02
Table 5  Associations of total poly(GP) levels or pTDP-43 pathology with cognitive score or neuropathological diagnosis in the clinical cohort
Spearman’s r correlation coefficients, 95 % confidence intervals (CIs), median (IQR), and p values are presented
Units for median values of poly(GP) levels are ng/mg protein
pTDP-43 pathology was quantified from sections immunostained with anti-pTDP-43 followed by measurement of immunopositivity of scanned 
images using a color deconvolution algorithm; median values for pTDP-43 are in arbitrary units
Given the assessment of poly(GP) levels or pTDP-43 pathology with two variables (i.e. cognitive score and neuropathological diagnosis), p val-
ues lower than 0.025 were considered significant after Bonferroni correction
p values denoted by bold remain significant after adjustment for multiple testing
ALS amyotrophic lateral sclerosis, FTLD-MND frontotemporal lobar degeneration with motor neuron disease
Cognitive score Neuropathological diagnosis (ALS vs. FTLD-MND)
Spearman’s r (95 % CI) p value ALS FTLD-MND p value
Poly(GP) levels
 Cerebellum 0.67 (0.22 to 0.88) 0.009 1122 (1005–1708) 3583 (2901–4139) 0.0008
 Frontal cortex −0.01 (−0.53 to 0.52) 0.90 692 (460–815) 771 (621–918) 0.33
 Motor cortex 0.18 (−0.38 to 0.64) 0.51 553 (464–582) 781 (678–954) 0.05
 Hippocampus 0.09 (−0.45 to 0.59) 0.74 308 (231–486) 558 (513–780) 0.07
pTDP-43 pathology
 Frontal cortex 0.58 (0.09 to 0.85) 0.03 0.0008 (0.0004–0.001) 0.003 (0.002–0.008) 0.01
 Hippocampus 0.50 (−0.03 to 0.81) 0.06 0.0005 (0.0002–0.001) 0.006 (0.003–0.01) 0.01
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using a quantitative analysis of inclusion pathology, 
Schuldi et al. reported that inclusions of poly(GA) are less 
frequent in cerebellar granule cells of patients with ALS 
(n = 3) and FTLD-MND (n = 8) compared to patients with 
FTLD (n = 3) [30]. This data differs from our observations 
that cerebellar poly(GA) trended lower in patients with 
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Fig. 4  Cerebellar poly(GP) associates with cognitive score and dif-
fers based on neuropathological subgroup in the clinical cohort of 
C9ORF72 mutation carriers. Four evaluators assessed cognitive 
function of patients in the clinical cohort (n = 15) from independ-
ent review of clinical records and test results, and assigned to each 
patient a score (0 = normal, 1 = mild or questionable impairment, or 
2 = definitely abnormal). The final cognitive score for each patient 
is the average of the scores assigned by the four evaluators. Associa-
tions of total poly(GP) in the cerebellum with cognitive score (a) or 
neuropathological diagnosis (b) of patients are shown. In panel a, the 
straight line is a linear regression line. In panel b, the median in a 
given group is denoted by a solid horizontal line. Red circles repre-
sent patients neuropathologically diagnosed with amyotrophic lateral 
sclerosis (ALS), and blue circles represent patients with frontotempo-
ral lobar degeneration with motor neuron disease (FTLD-MND)
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Fig. 5  Cerebellar poly(GA) levels in C9ORF72 mutation carri-
ers with ALS, FTLD or FTLD-MND, and associations between 
poly(GA) and C9ORF72 transcript variant 3 expression. a Poly(GA)-
immunoreactive inclusions in the cerebellum of a C9ORF72 repeat 
expansion carrier. Scale bar 5 µm. b Shown are total levels of cer-
ebellar poly(GA) by disease subgroup [amyotrophic lateral sclerosis 
(ALS), n = 12; frontotemporal lobar degeneration (FTLD), n = 24; 
and FTLD with motor neuron disease (FTLD-MND), n = 19]. The 
median in a given group is denoted by a solid horizontal line. c Asso-
ciations of poly(GA) levels in the cerebellum with expression of 
C9ORF72 transcript variant 3 (n = 49). The straight line is a linear 
regression line
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ALS (n = 12) compared to patients with FTLD (n = 24) as 
well as patients with FTLD-MND (n = 19). Yet, it must be 
kept in mind that the two studies used different case series 
and different methods to quantify poly(GA) burden.
The impetus for employing a biochemical approach to 
evaluate c9RAN proteins in this study was that it allows for 
non-biased, sensitive, and quantitative measures, and may 
permit the detection of a distinct pool of protein species 
not discernable by immunohistochemistry. With respect to 
the latter, we examined soluble and insoluble poly(GP) and 
poly(GA), finding a strong correlation between the solu-
ble and insoluble forms of each of these c9RAN proteins. 
We additionally observed that poly(GP) and poly(GA) 
have different solubility profiles in brain tissue. A greater 
percentage of total poly(GP) was soluble, while a greater 
percentage of total poly(GA) was insoluble. Whether and 
how this influences the toxic potential of these c9RAN pro-
teins is not yet known but worthy of investigation. Our data 
also suggest that poly(GA) levels are higher than levels of 
poly(GP); however, a direct comparison in the abundance 
of these two proteins should be made with some caution 
given the different biochemical properties of the proteins, 
differences in affinities of the poly(GP) and poly(GA) anti-
bodies used for the immunoassays, and differences in the 
calibrators used for interpolating protein concentrations.
Little is known about factors that govern c9RAN protein 
expression. We detected an association between cerebellar 
poly(GP) or poly(GA) levels and C9ORF72 transcript vari-
ant 3, the pre-mRNA of which contains the expanded repeat 
that serves as a template for RAN translation. Surprisingly, 
the same association was not observed for transcript variant 
1. Although pre-mRNA of variant 1 also contains the repeat 
expansion, one could speculate that the absence of an asso-
ciation may be a reflection of unique properties of each 
transcript variant (i.e. predisposition to RAN translation), 
which requires further study. There was no association 
between poly(GP) or poly(GA) levels in the cerebellum or 
frontal cortex with repeat size. This is congruent with our 
previous report that repeat size does not differ between 
disease subgroups [36], in contrast to what we show here 
for cerebellar poly(GP) levels. It is also worth noting that 
poly(GP) expression is higher in the cerebellum compared 
to the frontal cortex (Fig. 1), whereas repeat lengths in the 
cerebellum are smaller than those in the frontal cortex [36].
Of importance, the findings herein add to a growing body 
of evidence supporting cerebellar involvement in c9FTD/ALS. 
For instance, we discovered far more transcriptome changes in 
the cerebellum than frontal cortex of c9ALS patients [27], and 
cerebellar atrophy is reported in C9ORF72 expansion carriers 
with neuroimaging methods [17, 32, 38]. Furthermore, with 
regards to the association of cerebellar poly(GP) with cogni-
tive impairment, neuroanatomical studies have revealed recip-
rocal cerebellar connectivity with areas of the cerebral cortex 
involved in higher cognitive functioning. Output projections 
from the cerebellum first synapse on the dentate nucleus and 
then the thalamus before projecting to the cerebral cortex. 
Conversely, the cerebral cortex connects to the cerebellum via 
projections that synapse on the pons [7]. It is also notable that 
cerebellar activation during cognitive tasks has been recorded 
by functional neuroimaging [24], and that neuropsychologi-
cal studies on patients with cerebellar lesions have identified 
cognitive and affective disturbances, leading to the concept of 
“cerebellar cognitive affective syndrome” [31]. A large spec-
trum of deficits has been described in patients with cerebel-
lar damage, including executive dysfunction, mild language 
symptoms, blunting of affect, disinhibition, obsessive–com-
pulsive traits, and psychosis. Patients with C9ORF72 repeat 
expansions present with many similar features [29].
Whereas TDP-43 pathology is reportedly consistent in 
FTLD and ALS patients with and without the C9ORF72 
repeat expansion [9], neuropsychiatric symptoms, as well 
as cognitive and behavioral impairment, may be more com-
mon in FTD and ALS patients that carry the C9ORF72 
mutation compared to non-carriers [8, 29]. Features unique 
to the C9ORF72 repeat expansion, such as c9RAN pro-
teins, may thus contribute to the increased frequency of 
certain phenotypes in c9FTD/ALS. Indeed, we noted that 
one ALS patient with definite cognitive impairment, who 
was neuropathologically diagnosed with ALS, had sparse 
extramotor TDP-43 pathology but relatively high cerebel-
lar poly(GP) levels (Fig. 4). In a similar manner, abundant 
poly(GA) pathology in cerebral cortical regions, hippocam-
pus, and cerebellum, but only sparse TDP-43 pathology, 
0
20
40
60
80
100
P
er
ce
nt
ag
e 
of
 T
ot
al
 P
ol
y(
G
P
) L
ev
el
s
p<0.0001
Soluble Insoluble Soluble Insoluble
0
20
40
60
80
100
P
er
ce
nt
ag
e 
of
 T
ot
al
 P
ol
y(
G
A
) L
ev
el
s
p<0.0001
Poly(GP) Poly(GA)
Fig. 6  Solubility profiles of poly(GP) and poly(GA) in the cerebel-
lum. Comparison of soluble and insoluble poly(GP) or poly(GA) 
in the cerebellum of patients with C9ORF72 repeat expansions 
(n = 55). Note that soluble poly(GP) levels were significantly higher 
than insoluble poly(GP) levels, whereas soluble poly(GA) levels were 
significantly lower than insoluble poly(GA) levels. The median in a 
given group is denoted by a solid horizontal line
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have been reported in three C9ORF72 repeat expansion 
patients who developed fairly rapid cognitive decline, but 
died prematurely due to unrelated illnesses [4]. While data 
from our group and others [4, 26], indicate that clinical fea-
tures can develop in C9ORF72 repeat expansion carriers 
with c9RAN protein pathology but limited TDP-43 pathol-
ogy, we did nonetheless uncover a correlation between 
c9RAN proteins and pTDP-43. While levels of poly(GP) 
and poly(GA) in the frontal cortex or hippocampus did 
not associate with pTDP-43 pathology in these same 
regions, there were significant associations of poly(GP) or 
poly(GA) levels in the cerebellum with pTDP-43 pathology 
in the frontal cortex or hippocampus. These findings could 
point toward a relationship whereby cerebellar c9RAN pro-
teins influence TDP-43 in the frontal cortex and hippocam-
pus, or simply reflect the fact that cerebellar c9RAN pro-
tein levels and pTDP-43 pathology in the frontal cortex and 
hippocampus independently associate with neuropathologi-
cal diagnosis and consequently associate with each other. 
Nevertheless, the finding that poly(GA) levels in cerebel-
lum associated with pTDP-43 pathology in the frontal cor-
tex adds strength to the notion that, like poly(GP), cerebel-
lar poly(GA) differs based on neuropathological subgroup.
Overall, our findings implicate cerebellar abnormalities 
as a contributor to the neuropathological and clinical het-
erogeneity associated with the C9ORF72 repeat expansion, 
and support additional investigations on the role of this 
largely overlooked neuroanatomical region in c9FTD/ALS.
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